Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Common Equity (2016 - 2025)

AC Immune (ACIU) has disclosed Common Equity for 10 consecutive years, with $56.2 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 56.18% to $56.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.2 million through Dec 2025, down 56.18% year-over-year, with the annual reading at $56.2 million for FY2025, 56.18% down from the prior year.
  • Common Equity for Q4 2025 was $56.2 million at AC Immune, down from $128.2 million in the prior quarter.
  • The five-year high for Common Equity was $251.6 million in Q4 2021, with the low at $56.2 million in Q4 2025.
  • Average Common Equity over 5 years is $158.5 million, with a median of $175.4 million recorded in 2022.
  • The sharpest move saw Common Equity rose 5.55% in 2021, then crashed 56.18% in 2025.
  • Over 5 years, Common Equity stood at $251.6 million in 2021, then plummeted by 30.27% to $175.4 million in 2022, then rose by 3.24% to $181.1 million in 2023, then fell by 29.23% to $128.2 million in 2024, then plummeted by 56.18% to $56.2 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $56.2 million, $128.2 million, and $181.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.